CD274 and neoplasm: These advances rely on our growing understanding of tumor immune escape mechanisms and discoveries regarding immune checkpoint inhibitors and immune co-stimulating molecules, such as the PD-1 receptor and its ligands PD-L1 and PD-L2 [86].